Oragenics appoints Charles Pope as its new Board Chairman

– USA, FL –  Oragenics, Inc. (NYSE American: OGEN), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced the appointment of Charles Pope as its Chairman of the Board of Directors succeeding Dr. Fred W. Telling who will remain on the Board as an independent director.

Mr. Pope said: “As Board Chairman, I look forward to working with our Board members, including Fred, and the management team to realize the Company’s plans for the future. We hope to achieve continued progress in advancing the development of our product candidates.”

About Oragenics, Inc.

Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases caused by coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the National Institutes of Health and the National Research Council of Canada to reduce viral transmission and offer a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics.

For more information: https://www.oragenics.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.